Sysmex (OTCMKTS:SSMXY) Issues FY 2024 Earnings Guidance

Sysmex (OTCMKTS:SSMXYGet Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 0.580-0.580 for the period. The company issued revenue guidance of $3.3 billion-$3.3 billion.

Sysmex Trading Down 0.3 %

OTCMKTS:SSMXY opened at $18.22 on Wednesday. Sysmex has a 12-month low of $14.38 and a 12-month high of $28.58. The company has a current ratio of 3.19, a quick ratio of 2.42 and a debt-to-equity ratio of 0.11. The stock’s 50 day simple moving average is $18.92 and its 200-day simple moving average is $19.02. The firm has a market cap of $11.47 billion, a P/E ratio of 36.91 and a beta of 0.90.

Sysmex (OTCMKTS:SSMXYGet Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter. Equities analysts anticipate that Sysmex will post 0.57 EPS for the current year.

About Sysmex

(Get Free Report)

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.

Further Reading

Receive News & Ratings for Sysmex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sysmex and related companies with MarketBeat.com's FREE daily email newsletter.